Abstract
Recent advances in oligonucleotide microarray technology (“gene chips”) permit rapid screening for DNA sequence variation. The CYP2D6 gene encodes debrisoquine hydroxylase, which metabolizes the antidepressant nortriptyline and other psychotropic medications. Nortriptyline plasma concentrations were obtained after at least three weeks of treatment in 36 geriatric patients with major depression who were taking a mean of 8.6 other medications besides nortriptyline. Oligonucleotide microarrays were used to detect 16 CYP2D6 alleles that affect debrisoquine hydroxylase activity. Subjects carrying alleles encoding impaired debrisoquine hydroxylase activity had significantly greater nortriptyline concentrations and lower nortriptyline doses than did other subjects. Significant correlations were found between the numbers of alleles encoding decreased metabolism and nortriptyline plasma concentration, nortriptyline dose, and nortriptyline plasma concentration standardized for dose, indicating a gene dosage effect. These results demonstrate that CYP2D6 genotyping on a microarray platform can be used to predict plasma antidepressant concentrations despite advanced patient age and numerous concurrent medications.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Alon U, Barkai N, Notterman DA, Gish K, Ybarra S, Mack D, Levine AJ . (1999): Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci USA 96: 6745–6750
Bertilsson L, Dahl ML, Tybring G . (1997): Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl 391: 14–21
Burke MJ, Preskorn SH . (1999): Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice. Clin Pharmacokinet 37: 147–165
Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES . (1999): Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 22: 231–238
Chee M, Yang R, Hubbell E, Berno A, Huang XC, Stern D, Winkler J, Lockhart DJ, Morris MS, Fodor SP . (1996): Accessing genetic information with high-density DNA arrays. Science 274: 610–614
Coutts RT . (1994): Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping. J Psychiatry Neurosci 19: 30–44
Dahl ML, Bertilsson L, Nordin C . (1996): Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology 123: 315–319
Dalen P, Dahl ML, Ruiz ML, Nordin J, Bertilsson L . (1998): 10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 63: 444–452
Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM . (1996): Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6: 193–201
Fodor S . (1997): Massively parallel genomics. Science 277: 393–395
Hirschhorn JN, Sklar P, Lindblad-Toh K, Lim YM, Ruiz-Gutierrez M, Bolk S, Langhorst B, Schaffner S, Winchester E, Lander ES . (2000): SBE-TAGS: An array-based method for efficient single-nucleotide polymorphism genotyping. Proc Natl Acad Sci USA 97: 12164–12169
Lee CK, Klopp RG, Weindruch R, Prolla TA . (1999): Gene expression profile of aging and its retardation by caloric restriction. Science 285: 1390–1393
Linder MW, Prough RA, Valdes R Jr . (1997): Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 43: 254–266
Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, Meyer UA, Broly F . (1997): Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7: 193–202
Morita S, Shimoda K, Someya T, Yoshimura Y, Kamijima K, Kato N . (2000): Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J Clin Psychopharmacol 20: 141–149
Mulsant BH, Foglia JP, Sweet RA, Rosen J, Lo KH, Pollock BG . (1997): The effects of perphenazine on the concentration of nortriptyline and its hydroxymetabolites in older patients. J Clin Psychopharmacol 17: 318–321
Olesen OV, Linnet K . (1997): Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metabolism and Disposition 25: 740–744
Perry PJ, Zeilmann C, Arndt S . (1994): Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 14: 230–240
Pollock BG . (1999): Adverse reactions of antidepressants in elderly patients. Journal of Clinical Psychiatry 60 Suppl 20: 4–8
Pollock BG, Everett G, Perel JM . (1992): Comparative cardiotoxicity of nortriptyline and its isomeric 10-hydroxymetabolites. Neuropsychopharmacology 6: 1–10
Pollock BG, Perel JM, Paradis CF, Fasiczka AL, Reynolds III CF . (1994): Metabolic and physiologic consequences of nortriptyline treatment in the elderly. Psychopharmacol Bull 30: 145–150
Potter WZ, Manji HK, Rudorfer MV . (1998): Tricyclics and tetracyclics. In Schatzberg AF, Nemeroff CB (eds), Textbook of Psychopharmacology, 2nd ed. Washington, DC, American Psychiatric Press, pp 199–218
Reynolds CF, 3rd, Perel JM, Frank E, Cornes C, Miller MD, Houck PR, Mazumdar S, Stack JA, Pollock BG, Dew MA, Kupfer DJ . (1999): Three-year outcomes of maintenance nortriptyline treatment in late-life depression: a study of two fixed plasma levels. Am J Psychiatry 156: 1177–1181
Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, Curdue K, Petracca G, Starkstein SE . (2000): Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: A placebo-controlled, double-blind study. Am J Psychiatry 157: 351–359
Sachse C, Brockmoller J, Bauer S, Roots I . (1997): Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60: 284–295
Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK . (1995): Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 5: 215–223
Watson SJ, Akil H . (1999): Gene chips and arrays revealed: a primer on their power and their uses. Biol Psychiatry 45: 533–543
Yue QY, Zhong ZH, Tybring G, Dalen P, Dahl ML, Bertilsson L, Sjoqvist F . (1998): Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 64: 384–390.
Acknowledgements
Supported by grants from the Nancy Pritzker Network for the Study of Depression, the National Institute of Mental Health (MH01239, MH01509, MH52247, MH55106, MH30915, and MH40041), The National Alliance for Research on Schizophrenia and Depression, and the Department of Veterans Affairs (Sierra-Pacific Mental Illness Research, Education, and Clinical Center).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Murphy, G., Pollock, B., Kirshner, M. et al. CYP2D6 Genotyping with Oligonucleotide Microarrays and Nortriptyline Concentrations in Geriatric Depression. Neuropsychopharmacol 25, 737–743 (2001). https://doi.org/10.1016/S0893-133X(01)00289-5
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(01)00289-5
Keywords
This article is cited by
-
Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study
Malaria Journal (2018)
-
Exploring the role of drug-metabolising enzymes in antidepressant side effects
Psychopharmacology (2015)
-
Technology platforms for pharmacogenomic diagnostic assays
Nature Reviews Drug Discovery (2004)
-
Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics
The Pharmacogenomics Journal (2002)
